Plasma levels of IL-7 and IL-15 after reduced intensity conditioned allo-SCT and relationship to acute GVHD

Bone Marrow Transplantation

Volumn 46, Issue 10, 2011, Pages 1374-1381

  Thiant, S ^a   Labalette, M ^a,b   Trauet, J ^b   Coiteux, V ^b   De Berranger, E ^b   Dessaint, J P ^a,b   Yakoub Agha, I ^a,b  

^a UNIV LILLE   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

acute GVHD allo SCT; CRP; IL 15; IL 7; IL 7Ra

Indexed keywords

AMSACRINE; BUSULFAN; C REACTIVE PROTEIN; CYCLOPHOSPHAMIDE; CYTARABINE; FLUDARABINE; INTERLEUKIN 15; INTERLEUKIN 7; INTERLEUKIN 7 RECEPTOR ALPHA; MELPHALAN; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GRAFT RECIPIENT; HLA MATCHING; HOMEOSTASIS; HUMAN; LYMPHOCYTE COUNT; MALE; MYELODYSPLASTIC SYNDROME; MYELOMA; MYELOPROLIFERATIVE DISORDER; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REDUCED INTENSITY CONDITIONING;

ADOLESCENT; ADULT; AGED; FEMALE; FLOW CYTOMETRY; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INTERLEUKIN-15; INTERLEUKIN-7; MALE; MIDDLE AGED; TRANSPLANTATION CONDITIONING; YOUNG ADULT;

EID: 80054001703     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2010.300     Document Type: Article

References (36)

1. Mielcarek M, Storb R. Graft-vs-host disease after non-myeloablative hematopoietic cell transplantation. Leuk Lymphoma 2005; 46: 1251-1260. (Pubitemid 41269290)
2. Johnston L. Acute graft-versus-host disease: differing risk with differing graft sources and conditioning intensity. Best Pract Res Clin Haematol 2008; 21: 177-192. (Pubitemid 351712712)
3. Michallet M, Le QH, Mohty M, Pre?bet T, Nicolini F, Boiron JM et al. Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Sociéte Française de Greffe de Moelle et de The?rapie Cellulaire. Exp Hematol 2008; 36: 535-544.
4. Storek J, Geddes M, Khan F, Huard B, Helg C, Chalandon Y et al. Reconstitution of the immune system after hematopoietic stem cell transplantation in humans. Semin Immunopathol 2008; 30: 425-437.
5. Seggewiss R, Einsele H. Immune reconstitution after allogeneic transplantation and expanding options for immunomodulation: an update. Blood 2010; 115: 3861-3868.
6. Landfried K, Wolff D, Holler E. Pathophysiology and management of graft-versus-host disease in the era f reduced-intensity conditioning. Curr Opin Oncol 2009; 21 (Suppl 1): S39-S41.
7. Ma A, Koka R, Burkett P. Diverse functions of IL-2, IL-15, and IL-7 in lymphoid homeostasis. Annu Rev Immunol 2006; 24: 657-679.
8. Mazzucchelli R, Durum S. Interleukin-7 receptor expression: intelligent design. Nat Rev Immunol 2007; 7: 144-154. (Pubitemid 46178275)
9. Fry T, Mackall C. The many faces of IL-7: from lymphopoiesis to peripheral T cell maintenance. J Immunol 2005; 174: 6571-6576. (Pubitemid 40705615)
10. Alpdogan O, Eng J, Muriglan S, Willis L, Hubbard V, Tjoe K et al. Interleukin-15 enhances immune reconstitution after allogeneic bone marrow transplantation. Blood 2005; 105: 865-873. (Pubitemid 40070777)
11. Sandau MM, Winstead CJ, Jameson SC. IL-15 is required for sustained lymphopenia-driven proliferation and accumulation of CD8T cells. J Immunol 2007; 179: 120-125. (Pubitemid 46986525)
12. Boyiadzis M, Memon S, Carson J, Allen K, Szczepanski MJ, Vance BA et al. Up-regulation of NK cell activating receptors following allogeneic hematopoietic stem cell transplantation under a lymphodepleting reduced intensity regimen is associated with elevated IL-15 levels. Biol Blood Marrow Transplant 2008; 14: 290-300. (Pubitemid 351218196)
13. Thiant S, Yakoub-Agha I, Magro L, Trauet J, Coiteux V, Jouet JP et al. Plasma levels of IL-7 and IL-15 in the first month after myeloablative BMT are predictive biomarkers of both acute GVHD and relapse. Bone Marrow Transplant 2010; 45: 1546-1552.
14. Kumaki S, Minegishi M, Fujie H, Sasahara Y, Ohashi Y, Tsuchiya S et al. Prolonged secretion of IL-15 in patients with severe forms of acute graft-versus-host disease after allogeneic bone marrow transplantation in children. Int J Hematol 1998; 67: 307-312. (Pubitemid 28257143)
15. Sakata N, Yasui M, Okamura T, Inoue M, Yumura-Yagi K, Kawa K. Kinetics of plasma cytokines after hematopoietic stem cell transplantation from unrelated donors: the ratio of plasma IL-10/sTNFR level as a potential prognostic marker in severe acute graft-versus-host disease. Bone Marrow Transplant 2001; 27: 1153-1161. (Pubitemid 32600288)
16. Dulphy N, Haas P, Busson M, Belhadj S, Peffault de Latour R, Robin M et al. An unusual CD56bright CD16low NK cell subset dominates the early posttransplant period following HLA-matched hematopoietic stem cell transplantation. J Immunol 2008; 181: 2227-2237.
17. Dean R, Fry T, Mackall C, Steinberg SM, Hakim F, Fowler D et al. Association of serum interleukin-7 levels with the development of acute graft-versus-host disease. J Clin Oncol 2008; 26: 5735-5741.
18. Bolotin E, Annett G, Parkman R, Weinberg K. Serum levels of IL-7 in bone marrow transplant recipients: relationship to clinical characteristics and lymphocyte count. Bone Marrow Transplant 1999; 23: 783-788. (Pubitemid 29186888)
19. Micol JB, Berthon C, Tricot S, Terriou L, Darre? S, Cracco P et al. Allogeneic stem-cell transplantation with fludarabine and 2-Gy TBI-based conditioning regimen for chronic hematological malignancy: a study of 25 consecutive patients and a literature review. Leuk Lymphoma 2007; 48: 321-329. (Pubitemid 46994882)
20. Yakoub-Agha I, Saule P, Depil S, Micol JB, Grutzmacher C, Boulanger-Villard F et al. A high proportion of donor CD4+ T cells expressing the lymph node-homing chemokine receptor CCR7 increases incidence and severity of acute graft-versushost disease in patients undergoing allogeneic stem cell transplantation for hematological malignancy. Leukemia 2006; 20: 1557-1565. (Pubitemid 44264099)
21. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999; 401: 708-712.
22. Alizadeh M, Bernard M, Danic B, Dauriac C, Birebent B, Lapart C et al. Quantitative assessment of hematopoetic chimerism after bone marrow transplantation by real-time quantitative polymerase chain reaction. Blood 2002; 99: 4618-4625. (Pubitemid 34627235)
23. Fuji S, Kim SW, Fukuda T, Mori S, Yamasaki S, Morita-Hoshi Y et al. Preengraftment serum C-reactive protein (CRP) value may predict acute graft-versus-host disease and nonrelapse mortality after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2008; 14: 510-517. (Pubitemid 351494745)
24. Mohty M, Blaise D, Faucher C, Vey N, Bouabdallah R, Stoppa AM et al. Inflammatory cytokines and acute graftversus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation. Blood 2005; 106: 4407-4411. (Pubitemid 41775955)
25. Sportès C, Hakim FT, Memon SA, Zhang H, Chua KS, Brown MR et al. Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets. J Exp Med 2008; 205: 1701-1714. (Pubitemid 351962032)
26. Petersen SL, Ryder LP, Bjo? rk P, Madsen HO, Heilmann C, Jacobsen N et al. A comparison of T-, B-and NK-cell reconstitution following conventional or nonmyeloablative conditioning and transplantation with bone marrow or peripheral blood stem cells from human leucocyte antigen identical sibling donors. Bone Marrow Transplant 2003; 32: 65-72. (Pubitemid 36850282)
27. Scholl S, Mu? gge LO, Issa MC, Kasper C, Pachmann K, Ho? ffken K et al. Impact of early NK cell recovery on development of GvHD and CMV reactivation in dose-reduced regimen prior to allogeneic PBSCT. Bone Marrow Transplant 2005; 35: 183-190. (Pubitemid 40185935)
28. O'Brien S, Kantarjian H, Beran M, Smith T, Koller C, Estey E et al. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood 1993; 82: 1695-1700. (Pubitemid 23278758)
29. Yakoub-Agha I, Saule P, Magro L, Cracco P, Duhamel A, Coiteux V et al. Immune reconstitution following myeloablative allogeneic hematopoietic stem cell transplantation: the impact of expanding CD28negative CD8+ T cells on relapse. Biol Blood Marrow Transplant 2009; 15: 496-504.
30. Reddy V, Winer AG, Eksioglu E, Meier-Kriesche HU, Schold JD, Wingard JR. Interleukin 12 is associated with reduced relapse without increased incidence of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11: 1014-1021. (Pubitemid 41754720)
31. Lozza L, Rivino L, Guarda G, Jarrossay D, Rinaldi A, Bertoni F et al. The strength of T cell stimulation determines IL-7 responsiveness, secondary expansion, and lineage commitment of primed human CD4+ IL-7Rhi T cells. Eur J Immunol 2008; 38: 30-39.
32. Sereti I, Dunham RM, Spritzler J, Aga E, Proschan MA, Medvik K et al. IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection. Blood 2009; 113: 6304-6314.
33. Moxham VF, Karegli J, Phillips RE, Brown KL, Tapmeier TT, Hangartner R et al. Homeostatic proliferation of lymphocytes results in augmented memory-like function and accelerated allograft rejection. J Immunol 2008; 180: 3910-3918.
34. Miller JS, Weisdorf DJ, Burns LJ, Slungaard A, Wagner JE, Verneris MR et al. Lymphodepletion followed by donor lymphocyte infusion (DLI) causes significantly more acute graft-versus-host disease than DLI alone. Blood 2007; 110: 2761-2763. (Pubitemid 47523203)
35. Gendelman M, Hecht T, Logan B, Vodanovic-Jankovic S, Komorowski R, Drobyski W. Host conditioning is a primary determinant in modulating the effect of IL-7 on murine graft-versus-host disease. J Immunol 2004; 172: 3328-3336. (Pubitemid 38263725)
36. Levy Y, Lacabaratz C, Weiss L, Viard JP, Goujard C, Lelièvre JD et al. Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. J Clin Invest 2009; 119: 997-1007.